Interstitial lipoid pneumonia-A complication of intravenous administration of lipid emulsions in critically ill patients.

IF 3.4 3区医学 Q1 PATHOLOGY

Virchows Archiv Pub Date : 2024-12-19 DOI:10.1007/s00428-024-04000-6

E M V de Cuba, W Vreuls, C G Tan, D B Flieder, E Thunnissen

引用次数: 0

Abstract

Lipoid pneumonia is a rare entity most often associated with inhalation of foreign material (i.e. "fire-eater's lung"), silicone injection, and severe trauma. We present the case of a 61-year old man who developed acute respiratory distress syndrome following endoscopic retrograde cholangiopancreatography (ERCP) for cholelithiasis. Intensive care supportive therapy included mechanical ventilation, dialysis, and total parenteral nutrition. Unresolved pneumothorax necessitated lobectomy. Histology of the lobectomy specimen demonstrated massive intra-alveolar haemorrhage and numerous alveolar septal macrophages with clear cytoplasmic vacuoles. These findings were diagnostic of interstitial lipoid pneumonia due to intravenous administration of lipid emulsions. The differential diagnosis is also discussed. Although rare, interstitial lipoid pneumonia should be considered in critically ill patients presenting with an interstitial pattern of lung disease after intravenous administration of lipid emulsions.

查看原文本刊更多论文

间质性脂质性肺炎——重症患者静脉注射脂质乳的并发症。

脂质性肺炎是一种罕见的疾病，通常与吸入异物有关。“吞火人的肺”)，硅胶注射，以及严重的创伤。我们提出的情况下，61岁的男子谁发展急性呼吸窘迫综合征内镜逆行胆管胰胆管造影（ERCP）胆石症。重症监护支持治疗包括机械通气、透析和全肠外营养。未解决的气胸需要肺叶切除术。肺叶切除标本的组织学显示大量肺泡内出血和大量肺泡间隔巨噬细胞伴清晰的细胞质空泡。这些结果是诊断间质性脂质性肺炎由于静脉注射脂质乳。并讨论了鉴别诊断。虽然罕见，但在静脉注射脂质乳剂后出现肺间质型疾病的危重患者中，应考虑间质性脂质性肺炎。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Virchows Archiv 医学-病理学

CiteScore

7.40

自引率

2.90%

发文量

204

审稿时长

4-8 weeks

期刊介绍： Manuscripts of original studies reinforcing the evidence base of modern diagnostic pathology, using immunocytochemical, molecular and ultrastructural techniques, will be welcomed. In addition, papers on critical evaluation of diagnostic criteria but also broadsheets and guidelines with a solid evidence base will be considered. Consideration will also be given to reports of work in other fields relevant to the understanding of human pathology as well as manuscripts on the application of new methods and techniques in pathology. Submission of purely experimental articles is discouraged but manuscripts on experimental work applicable to diagnostic pathology are welcomed. Biomarker studies are welcomed but need to abide by strict rules (e.g. REMARK) of adequate sample size and relevant marker choice. Single marker studies on limited patient series without validated application will as a rule not be considered. Case reports will only be considered when they provide substantial new information with an impact on understanding disease or diagnostic practice.